Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Mixed chimaerism is commo… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation.

Artikel i vetenskaplig tidskrift
Författare Jonas Mattsson
M Uzunel
Mats Brune
P Hentschke
L Barkholt
Ulrika Stierner
J Aschan
O Ringdén
Publicerad i British journal of haematology
Volym 115
Nummer/häfte 4
Sidor 935-44
ISSN 0007-1048
Publiceringsår 2001
Publicerad vid Institutionen för särskilda specialiteter, Avdelningen för onkologi
Institutionen för invärtesmedicin, Avdelningen för internmedicin
Sidor 935-44
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adult, Aged, Bone Marrow Cells, pathology, Busulfan, therapeutic use, Cell Count, Cyclophosphamide, therapeutic use, Female, Graft vs Host Disease, immunology, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Immunosuppressive Agents, therapeutic use, Male, Middle Aged, T-Lymphocytes, pathology, Transplantation Conditioning, methods, Transplantation, Homologous, Treatment Outcome, Vidarabine, analogs & derivatives, therapeutic use, Whole-Body Irradiation
Ämneskategorier Cancer och onkologi

Sammanfattning

We report the clinical outcome and results of chimaerism analysis in various cell lineages of 30 patients given non-myeloablative conditioning, followed by allogeneic stem cell transplantation (SCT). The commonest diagnoses were chronic myelogenous leukaemia (n = 11) and solid tumours (n = 11). Twenty-one patients received SCT from human leucocyte antigen (HLA)-identical siblings and nine from matched unrelated donors. Median patient age was 53 (28-77) years. Four non-myeloablative protocols were used, including fludarabine (30 mg/m2 x 3-6), busulphan (4 mg/kg x 2), cyclophosphamide (Cy) (30 mg/kg/day x 2) or total body irradiation (2 Gy), and anti-thymocyte globulin. The patients were analysed by polymerase chain reaction (PCR) analysis of minisatellites on days 14, 21 and 28, then every other week up to 3 months and monthly thereafter. All samples were cell separated for T, B and myeloid cells using immunomagnetic beads. Eighteen patients were alive at a median follow-up of 11 (6-20) months. Acute graft-versus-host disease (GVHD) occurred in 22 patients. Eighteen of the 22 patients with acute GVHD showed mixed chimaerism (MC) in the T-cell fraction at the time of acute GVHD. However, all patients with acute GVHD showed donor chimaerism (DC) in the T-cell fraction median 76 (7-414) days after onset versus three out of eight patients without acute GVHD, P < 0.001]. Disease response was diagnosed in 15 patients, median 100 (37-531) days after SCT. At the time of disease response, six out of 15 patients showed MC in the T-cell fraction. In conclusion, mixed chimaerism in the T-cell fraction is common at the time of acute GVHD and disease response in patients conditioned with non-myeloablative therapy.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?